XML 29 R22.htm IDEA: XBRL DOCUMENT
v3.21.4

SHARE CAPITAL (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2021
Disclosure of classes of share capital [abstract] |
Disclosure of number and weighted average exercise prices of share options [Table Text Block] |
|  | Number of options |  |  | Weighted average exercise price |
Balance at September 30, 2019 and May 31, 2019 |  | - |  |  | - |
Granted |  | 150,000 |  | $ | 1.25 |
Balance at September 30, 2020 |  | 150,000 |  | $ | 1.25 |
Granted |  | 895,807 |  | $ | 4.29 |
Cancelled* |  | (20,000 | ) | $ | 1.25 |
Balance at September 30, 2021 |  | 1,025,807 |  | $ | 3.90 |
Disclosure of number of issued and outstanding stock options [Table Text Block] |
|  | Options Outstanding and Exercisable |
Expiry Date |  | Number of options |  |  | Exercisable |  |  | Exercise price |  |  | Remaining life (Years) |
September 21, 2024 |  | 8,807 |  |  | - |  | $ | 7.64 |  |  | 2.98 |
July 23, 2025 |  | 150,000 |  |  | 150,000 |  | $ | 1.25 |  |  | 3.81 |
November 17, 2025 |  | 447,000 |  |  | 30,500 |  | $ | 1.25 |  |  | 4.13 |
April 28, 2026 |  | 240,000 |  |  | - |  | $ | 7.60 |  |  | 4.58 |
June 15, 2026 |  | 180,000 |  |  | - |  | $ | 7.60 |  |  | 4.71 |
Disclosure of number and weighted average exercise prices of restricted share units [Table Text Block] |
|  | Equity settled |  |  | Cash settled |  |  | Total |
Balance at September 30, 2019 and May 31, 2019 |  | - |  |  | - |  |  | - |
Granted |  | 380,000 |  |  | - |  |  | 380,000 |
Balance at September 30, 2020 |  | 380,000 |  |  | - |  |  | 380,000 |
Vested |  | (95,000 | ) |  | - |  |  | (95,000 | )
Balance at September 30, 2021 |  | 285,000 |  |  | - |  |  | 285,000 |
Disclosure of equity-settled restricted share units fair value inputs [Table Text Block] |
|  | Year ended September 30, 2020 |
Share price on grant date | $ | 1.25 |
Forfeiture rate |  | 0% |
Disclosure of share based payments recognized in the consolidated statements of comprehensive loss [Table Text Block] |
|  | Year ended September 30, 2021 |  |  | Year ended September 30, 2020 |  |  | Period ended September 30, 2019 |
|  | $ |  |  | $ |  |  | $ |
Stock options |  | 643,963 |  |  | 138,000 |  |  | - |
Restricted share units - equity settled grants |  | 236,652 |  |  | 23,300 |  |  | - |
Total equity settled share-based compensation expense |  | 880,615 |  |  | 161,300 |  |  | - |
Restricted share units - cash settled grants |  | - |  |  | - |  |  | - |
Total share-based compensation expense |  | 880,615 |  |  | 161,300 |  |  | - |
Disclosure of share based payments included in the consolidated statements of comprehensive loss [Table Text Block] |
|  | Year ended September 30, 2021 |  |  | Year ended September 30, 2020 |  |  | Period ended September 30, 2019 |
|  | $ |  |  | $ |  |  | $ |
Consulting fees |  | 8,045 |  |  | - |  |  | - |
Directors' compensation |  | 136,612 |  |  | - |  |  | - |
Marketing, advertising and investor relations |  | 3,696 |  |  | - |  |  | - |
Professional fees |  | 23,126 |  |  | - |  |  | - |
Research and development |  | 709,136 |  |  | 161,300 |  |  | - |
Total share-based compensation expense |  | 880,615 |  |  | 161,300 |  |  | - |
Disclosure of number and weighted average exercise prices of warrants [Table Text Block] |
|  | Number of warrants |  |  | Weighted average exercise price |
Balance at September 30, 2019 and May 31, 2019 |  | - |  | $ | - |
Issued |  | 4,079,600 |  |  | 0.05 |
Balance at September 30, 2020 |  | 4,079,600 |  |  | 0.05 |
Issued* |  | 1,709,938 |  |  | 9.46 |
Issued - broker |  | 132,666 |  |  | 7.57 |
Exercised |  | (1,948,000 | ) |  | 0.05 |
Balance at September 30, 2021 |  | 3,974,204 |  | $ | 4.35 |
Disclosure of number of outstanding warrants [Table Text Block] |
|  | Warrants Outstanding |
Expiry Date |  | Number of warrants |  |  | Exercise price |  |  | Remaining life (Years) |
July 30, 2024 (1) |  | 2,131,600 |  | $ | 0.05 |  |  | 2.83 |
March 17, 2024 |  | 1,709,938 |  | $ | 9.46 |  |  | 2.46 |
March 17, 2024 |  | 132,666 |  | $ | 7.57 |  |  | 2.46 |

X
- Definition Disclosure about equity settled restricted share units fair value inputs. + References No definition available. + Details
Name: | drug_DisclosureOfDetailedInformationAboutEquitySettledRestrictedShareUnitsFairValueInputsExplanatory
Namespace Prefix: | drug_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of detailed information about share based payments included in consolidated statements of comprehensive loss statement. + References No definition available. + Details
Name: | drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsIncludedInConsolidatedStatementsOfComprehensiveLossExplanatory
Namespace Prefix: | drug_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of detailed information about share based payments recognized in the consolidated statements of comprehensive loss statement. + References No definition available. + Details
Name: | drug_DisclosureOfDetailedInformationAboutShareBasedPaymentsRecognizedInConsolidatedStatementsOfComprehensiveLossExplanatory
Namespace Prefix: | drug_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of number and weighted average exercise prices of warrants explanatory. + References No definition available. + Details
Name: | drug_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsExplanatory
Namespace Prefix: | drug_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of number of issued and outstanding stock options explanatory. + References No definition available. + Details
Name: | drug_DisclosureOfNumberOfIssuedAndOutstandingStockOptionsExplanatory
Namespace Prefix: | drug_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of number of issued and outstanding warrants explanatory. + References No definition available. + Details
Name: | drug_DisclosureOfNumberOfIssuedAndOutstandingWarrantsExplanatory
Namespace Prefix: | drug_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfClassesOfShareCapitalAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration